Medical Research
Understand how new medicines are tested, find trials near you, and know your rights as a participant.
Foundation
A clinical trial is a research study conducted in human beings that evaluates a medical, surgical, or behavioral intervention. Clinical trials are the primary mechanism through which scientists and physicians determine whether a new medicine, device, procedure, or behavioral strategy is safe and effective for use in people. Before any medication reaches a pharmacy shelf, it must pass through a rigorous sequence of clinical trials, each phase designed to answer progressively more detailed questions about safety, dosing, and therapeutic benefit.
Clinical trials fall into two fundamental categories: interventional and observational. Interventional trials — also called experimental studies or randomized controlled trials (RCTs) — assign participants to receive a particular treatment or intervention according to a protocol. Researchers actively administer the study treatment and measure outcomes under controlled conditions. Observational studies, by contrast, do not assign treatments; instead, investigators observe participants in their natural setting and collect data about exposures, behaviors, and outcomes.
Within the interventional category, trials serve four principal purposes: treatment trialstest new therapies (medicines, vaccines, surgical approaches, radiation protocols, or combinations thereof); prevention trials assess interventions that may stop disease from developing or recurring in healthy or at-risk individuals; diagnostic trials evaluate new tests or procedures for identifying disease; and quality-of-life trials examine ways to improve the comfort and quality of life for people with chronic illnesses or serious conditions.
Who runs clinical trials? The cast of stakeholders is broad. Pharmaceutical companies— from global giants like Pfizer, Roche, and AstraZeneca to small biotech startups — fund the majority of trials for commercial medicines and biologics. The National Institutes of Health (NIH), through institutes such as the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), sponsors trials focused on diseases where commercial interest may be limited or where public-health priorities demand independent research. Academic medical centers— Johns Hopkins, Mayo Clinic, MD Anderson, Memorial Sloan Kettering — conduct both industry-sponsored and investigator-initiated trials. Cooperative groups such as ECOG-ACRIN (oncology), SWOG (oncology), and ACTG (HIV/AIDS) coordinate large multi-site trials across dozens or hundreds of institutions simultaneously, enabling the large sample sizes needed to detect modest treatment effects.
From a regulatory standpoint, every clinical trial involving a medicine or biologic must operate under an Investigational New Medicine (IND) application — a submission to the FDA requesting authorization to conduct human studies with an unapproved agent. The IND must include the trial protocol (a detailed plan specifying objectives, design, methodology, statistical considerations, and participant protections), preclinical safety data, and manufacturing information. The entity legally responsible for initiating and conducting the trial is called the sponsor; the physician or scientist responsible at each study site is the principal investigator (PI). Together, sponsor and PI bear accountability for participant safety and scientific integrity.
The global scale of clinical research is staggering. As of 2025, more than 400,000 clinical studies are registered on ClinicalTrials.gov, the U.S. government's public registry maintained by the National Library of Medicine. These span every continent except Antarctica, every therapeutic area from rare genetic diseases to common conditions like hypertension and depression, and every phase of development. Each year, millions of people around the world participate as trial volunteers, making possible the advances in medicine that benefit all future patients.
For Patients
The decision to join a clinical trial is deeply personal, shaped by individual health circumstances, values, and priorities. There is no single right answer — but there are compelling reasons both for and against participation, and every prospective participant deserves a clear-eyed understanding of each.
One of the most powerful motivations is access to cutting-edge treatments before they receive regulatory approval. For patients with serious or life-threatening conditions who have exhausted standard therapies, a clinical trial may represent the only avenue to a potentially more effective intervention. Some participants in landmark trials — such as those testing the first checkpoint inhibitors for melanoma or the initial CAR-T cell therapies for leukemia — experienced remissions that were previously unimaginable with standard treatments.
Participants also receive close, expert medical monitoringfar more intensive than typical clinical care. Study teams — often including physicians, nurses, research coordinators, and pharmacists — track participants' health through regular visits, laboratory tests, imaging studies, and detailed safety evaluations. This heightened surveillance can detect health changes early, providing a layer of medical attention that patients outside trials may not experience.
In many trials, study-related medical care and investigational medicines are provided at no costto participants. While this is not universal (and participants should clarify exactly what costs are and are not covered before enrolling), the provision of free study medicines, tests, and clinical visits can meaningfully reduce financial burden for participants, particularly those managing expensive chronic conditions.
Beyond personal benefit, many participants are motivated by altruism— the knowledge that their participation contributes to science that will help future patients. This motivation is especially prominent among individuals who have lost family members to diseases that still lack effective treatments. As countless researchers and ethicists have noted: without volunteers, no new medicine could ever be evaluated in humans. Without clinical trial participants, the entire pipeline of medical progress grinds to a halt. Participation is, in a very real sense, an act of generosity with implications far beyond any individual's own health.
Clinical trial participation is not without real risks and burdens. The most fundamental concern is unknown side effects: by definition, investigational treatments have not been fully characterized in large populations. Phase I and Phase II trials in particular may uncover unexpected toxicities. Even Phase III trials sometimes miss rare adverse events that only emerge in post-market surveillance.
Participants may also be assigned to a placebo arm in randomized controlled trials — receiving an inert treatment rather than the experimental medicine. This is ethically acceptable when there is genuine uncertainty about which treatment is superior (the equipoise principle), but it means some participants will not receive the experimental therapy they hoped to access.
The time commitment is often substantial. Multi-site Phase III trials may require frequent clinic visits over months or years, blood draws, imaging studies, questionnaires, and travel to specialized research centers — all of which impose real costs in time, energy, and potentially money. Participants must also follow strict protocol requirements that may include dietary restrictions, avoiding certain medications, or refraining from activities that could affect trial results.
Who typically participates? Patients with specific diagnosed conditions who have tried standard therapies form the majority of participants in Phase II and III trials. Phase I oncology trials often enroll patients with advanced cancer who have no other treatment options. Phase I trials for non-oncology medicines frequently enroll healthy volunteers — individuals without the target disease — to establish safety and pharmacokinetics in a population free of confounding illness and medications.
Medicine Development
Phase 0 is a relatively recent, optional step in the medicine development process, formalized by the FDA in its 2006 Exploratory IND guidance. Phase 0 studies administer subtherapeutic doses — typically less than 1% of the expected therapeutic dose — to a very small number of participants (usually 6-15) to gather early pharmacokinetic (PK) and pharmacodynamic (PD) data in humans. The goal is not to assess therapeutic benefit or safety at therapeutic levels, but to quickly confirm that the medicine behaves in the human body as predicted by animal models, and to select the most promising candidate from multiple compounds before committing to the full expense of Phase I. Phase 0 is particularly used in oncology medicine development.
Phase I is the first time an investigational medicine is administered to humans at doses intended to produce a biological effect. The primary objectives are to characterize the medicine's safety profile and pharmacokinetics — how it is absorbed, distributed, metabolized, and excreted (ADME) — and to identify the maximum tolerated dose (MTD): the highest dose that can be given without unacceptable toxicity.
The most common Phase I design is the 3+3 dose escalation scheme: three participants receive an initial low dose. If none experiences a dose-limiting toxicity (DLT), three more receive a higher dose. If one of three experiences a DLT, three more participants are enrolled at the same dose level. The process continues upward in dose until the MTD is identified. Newer, more statistically sophisticated designs like the Bayesian Optimal Interval (BOIN) design and the Continual Reassessment Method (CRM) allow more efficient dose escalation while better protecting participants from excessive toxicity.
A dose-limiting toxicity (DLT) is a pre-specified severe adverse event that, per protocol, triggers a pause or reduction in dosing. DLT definitions typically reference the NCI Common Terminology Criteria for Adverse Events (CTCAE) grading system, with Grade 3 or 4 toxicities in specified organ systems serving as DLT criteria. The MTD is typically defined as the dose just below the one at which two or more of six participants experience a DLT.
In non-oncology indications, Phase I trials typically enroll healthy volunteers— individuals without the target disease — because the medicine's safety profile can be evaluated in a clean physiological context without the confounding effects of illness or concomitant medications. In oncology, however, Phase I trials almost universally enroll patients with advanced cancer who have no remaining standard treatment options, because it would be unethical to expose healthy individuals to potentially highly toxic experimental cancer medicines. Phase I trials typically enroll 20-100 participants and last 1-2 years.
Having established a safe dose range in Phase I, Phase II trials expand to 100-300 participants — typically patients with the target disease — and begin to assess whether the medicine actually works. Phase II answers three key questions: Is there a signal of therapeutic efficacy? What is the optimal dose for further study? What is the full adverse event profile at therapeutic doses?
Phase II trials are often randomized (with a control arm) but may also be single-arm studies where all participants receive the experimental medicine and outcomes are compared to historical benchmarks. In oncology, overall response rate (ORR) — the proportion of patients whose tumor shrinks by a pre-specified amount — is a commonly used Phase II endpoint because it can be measured in weeks to months, far faster than the survival endpoints needed for Phase III.
Statistically, Phase II trials are designed for go/no-go decisions rather than definitive proof of efficacy. Approximately 33% of medicines that enter Phase II advance to Phase III. The Phase II failure rate reflects the inherent difficulty of medicine development: even medicines that showed activity in cell culture and animal models often fail to demonstrate sufficient efficacy or an acceptable safety profile in human patients. Each Phase II failure, while costly to the sponsor, saves the far greater expense and participant burden of an unsuccessful Phase III trial.
Phase III trials are the pivotal studies that provide the definitive evidence for regulatory approval. They are typically large, multicenter, randomized controlled trials (RCTs) comparing the experimental treatment to a control arm — either placebo (when no effective treatment exists) or the current standard of care (when withholding treatment would be unethical). Sample sizes of 1,000 to 3,000+ participants are typical, driven by statistical power calculations designed to detect the expected treatment effect with acceptable alpha (probability of false positive) and beta (probability of false negative) errors.
The FDA requires that applications for most new medicines include evidence from at least two adequate and well-controlled Phase III studies, each independently demonstrating efficacy. The rationale is straightforward: the probability that two independent, well-designed trials both produce a false-positive result is extremely low. Some exceptions exist — a single convincing trial may suffice in cases where there is a large, robust treatment effect or where conducting two trials would be logistically impractical.
Phase III trials last 2-4 years on average, require enormous financial resources (often hundreds of millions of dollars), and demand extensive coordination across research sites in multiple countries. Despite these challenges, approximately 67% of medicines that enter Phase III ultimately receive regulatory approval — a testament to the increasingly rigorous selection that occurs in Phases I and II.
Phase IV refers to studies conducted after a medicine has received regulatory approval and is available on the market. These studies serve several critical purposes. First, they monitor for rare adverse events that could not have been detected in Phase III: a serious side effect occurring in 1 in 10,000 patients would require a trial of 30,000+ participants to reliably detect, far beyond typical Phase III enrollment. Second, Phase IV studies may support label expansions — new indications, new dosage forms, or use in new populations (pediatric, geriatric, renally impaired). Third, they may fulfill requirements imposed by regulatory agencies as conditions of approval.
Post-market safety studies may be required through a Risk Evaluation and Mitigation Strategy (REMS) or through the EMA's analogous Post-Authorization Safety Studies (PASS). Pharmacoeconomicstudies — evaluating cost-effectiveness and budget impact — are also commonly conducted in Phase IV to support payer reimbursement decisions. The FDA's MedWatch program and the Sentinel System provide ongoing pharmacovigilance infrastructure that continuously monitors approved medicines for emerging safety signals throughout their marketed life.
Ethics & Protections
Informed consent is the process through which a prospective trial participant is provided with comprehensive information about a study and voluntarily agrees to participate. It is not merely a signature on a form — it is an ongoing communication process that must occur before any study-related procedures begin and must continue throughout the trial as new information emerges. Federal regulations (FDA 21 CFR Part 50 and DHHS 45 CFR Part 46) specify eight required elements that every informed consent document must contain:
One of the most fundamental protections in clinical research is the right to withdraw at any time, for any reason, without penalty or loss of medical benefits. This is not merely a formality — it is a hard legal and ethical requirement. A participant who decides on Monday morning that they no longer wish to continue may leave without providing a reason, and the research team must honor that decision immediately. No financial incentive, social pressure from the research team, or fear of losing ongoing medical care can ethically be used to coerce continued participation.
Every clinical trial conducted at a U.S. institution must be reviewed and approved by an Institutional Review Board (IRB) — an independent committee of scientists, ethicists, community members, and patient advocates charged with protecting the rights and welfare of research participants. IRBs review the trial protocol before it begins, must approve all amendments to the protocol during the trial, receive annual reports on ongoing trials, and must be notified immediately of any unanticipated problems involving risks to participants or others. Federal requirements mandate that every IRB include at least five members with varying backgrounds and that at least one member must be unaffiliated with the institution.
The Health Insurance Portability and Accountability Act (HIPAA) applies to research settings when covered entities (hospitals, clinics) use or disclose protected health information (PHI) for research purposes. Participants must provide specific authorization for their PHI to be used in research, or the IRB must grant a waiver. Many federally funded studies also provide a Certificate of Confidentiality (CoC) — a legal protection that prevents researchers from being compelled by subpoena or court order to reveal identifiable research data, protecting participants from the possibility that sensitive health information could be used against them in legal or employment contexts.
Current research ethics protections did not emerge from abstract philosophy — they were forged in response to real historical abuses. The Tuskegee Syphilis Study (1932-1972), in which Black men with syphilis were observed but never treated even after penicillin became the standard cure, stands as the most notorious example of research conducted without genuine informed consent or participant protection. The public revelation of Tuskegee directly prompted the National Research Act of 1974, the creation of the National Commission for the Protection of Human Subjects, and the landmark Belmont Report (1979) — which established three foundational ethical principles for research: respect for persons (autonomy and informed consent), beneficence (maximize benefit and minimize harm), and justice (fair distribution of research burdens and benefits across populations). The international Declaration of Helsinki, first adopted by the World Medical Association in 1964 and updated multiple times since, provides the global framework for research ethics.
How To
ClinicalTrials.gov is the world's largest publicly accessible registry and results database of clinical studies, maintained by the U.S. National Library of Medicine (NLM). Since 2000, federal law has required the registration of most clinical trials involving FDA-regulated interventions and, since 2017, the submission of results. The database provides free, searchable access to information on more than 400,000 studies worldwide.
Study Status:"Recruiting" means the trial is actively looking for participants. Other statuses include "Active, not recruiting" (enrollment closed, study ongoing), "Completed," and "Terminated" (stopped early).
Eligibility Criteria:This is the most critical section for prospective participants. Inclusion criteria specify who qualifies (e.g., "Adults 18-75 years with confirmed Stage III non-small cell lung cancer"); exclusion criteria specify who cannot participate (e.g., "Prior platinum-based chemotherapy," "ECOG performance status ≥ 3", or "Significant hepatic impairment defined as AST/ALT > 3× ULN"). The ECOG performance status scale (0-4) measures a cancer patient's level of functioning; most trials require ECOG 0-2.
Primary Outcome:The main endpoint the trial is designed to evaluate — the measurement on which the study's success or failure will ultimately be judged.
Estimated Completion Date: Helps you understand how long you would be committed to the study.
ClinicalTrials.gov is not the only registry. The WHO International Clinical Trials Registry Platform (ICTRP) aggregates data from multiple national registries including ClinicalTrials.gov and provides a single portal for searching globally registered studies. The EU Clinical Trials Register (clinicaltrialsregister.eu) covers trials conducted under the European Clinical Trials Directive. The ISRCTN registry (International Standard Randomised Controlled Trial Number) is another internationally recognized registry particularly prominent in UK and European trials. Searching multiple registries may surface trials not listed in ClinicalTrials.gov, particularly international studies.
Research Methods
Randomization is the process of using chance — rather than investigator or participant preference — to assign participants to study groups. It is the single most important design feature of a clinical trial because it eliminates selection bias: without randomization, investigators might (consciously or unconsciously) assign sicker or healthier patients to particular treatment arms, making it impossible to determine whether observed differences in outcomes are due to the treatment or pre-existing differences between groups.
Simple randomization uses a random number generator to assign participants, like flipping a coin for each participant. This works well for large trials but can produce unequal group sizes in smaller trials. Block randomization uses pre-defined blocks (e.g., blocks of 4) to ensure that equal numbers are assigned to each arm within each block, maintaining approximate balance throughout the trial. Stratified randomization first divides participants by prognostic factors (e.g., disease stage, age group, center) and then randomizes within each stratum, ensuring that important prognostic variables are equally distributed across treatment arms.
Blinding prevents knowledge of treatment assignment from influencing participant or investigator behavior and assessments. In a single-blind trial, participants do not know which treatment they are receiving, but investigators do. In a double-blind trial — the gold standard — neither participants nor the investigators assessing outcomes know the treatment assignment. Triple-blind designs extend concealment to the statisticians analyzing the data. Some trials cannot be blinded (open-label) due to obvious differences between treatments (e.g., surgery vs. medicine, or two medicines with very different dosing schedules), but wherever possible, blinding is maintained to minimize bias.
A placebo is an inert treatment — a pill, injection, or procedure that looks like the experimental treatment but contains no active therapeutic ingredient. Using a placebo control allows investigators to separate the true pharmacological effect of a medicine from the psychological and expectation-driven effects of receiving treatment (the "placebo effect"). However, the use of a placebo is only ethically permissible when there is genuine clinical equipoise — that is, when the medical community has genuine uncertainty about whether the experimental treatment is superior to no treatment or to current standard of care. If an effective treatment already exists for the condition, it would be unethical to assign participants to placebo; instead, the control arm receives the best available existing therapy.
In a crossover design, participants receive both treatments sequentially — first one, then (after a washout period to eliminate carry-over effects) the other. Each participant serves as their own control, reducing between-participant variability and often allowing smaller sample sizes. Crossover designs are particularly well-suited to stable chronic conditions and to pharmacokinetic studies.
Adaptive trial designs allow pre-specified modifications to the trial based on interim data — adjusting sample size, dropping ineffective arms, or modifying the randomization ratio — while maintaining statistical validity. Platform trials and master protocols (umbrella and basket trials) are innovative designs that test multiple treatments or tumor types simultaneously within a common framework, dramatically increasing research efficiency.
A superiority trial tests whether a new treatment is better than the comparator. A non-inferiority trial tests whether a new treatment is not unacceptably worse than an established treatment — acceptable when the new treatment offers compensating advantages such as better tolerability, simpler dosing, or lower cost. An equivalence trialtests whether two treatments produce essentially the same outcomes within a predefined margin in both directions. The choice of trial type profoundly affects sample size, analysis, and how results should be interpreted.
Interpreting Evidence
Every trial is powered to detect a specific primary endpoint — the single most important outcome measure specified in the protocol before the trial begins. The entire sample size and statistical analysis plan is built around detecting a meaningful difference on this outcome. Common primary endpoints include overall survival (OS), progression-free survival (PFS), overall response rate (ORR), A1c reduction, blood pressure change, and clinical remission scores. Secondary endpoints provide additional information but are considered exploratory and hypothesis-generating rather than definitive — a positive result on a secondary endpoint alone cannot be used to claim a medicine works.
A p-value below 0.05 indicates statistical significance — that the observed treatment effect is unlikely to have occurred by chance if the null hypothesis (no difference) were true. But statistical significance is not the same as clinical significance. A very large trial may detect a 0.5 mmHg reduction in blood pressure that is statistically significant but clinically meaningless. Conversely, a small trial may produce a clinically important finding that falls just above the p = 0.05 threshold due to insufficient power. Always consider the magnitude of the effect alongside the p-value.
Confidence intervals (95% CI) provide much richer information than p-values alone. A 95% CI represents the range of values within which the true treatment effect is likely to lie with 95% probability. A narrow CI indicates a precise estimate; a wide CI indicates uncertainty. If the CI for an efficacy measure excludes zero (or 1.0 for ratio measures like hazard ratios and odds ratios), the result is statistically significant at the 5% level.
In oncology and cardiovascular trials where time-to-event endpoints are used, results are often reported as hazard ratios (HR) with accompanying Kaplan-Meier (K-M) survival curves. The HR compares the rate of an event (death, disease progression, hospitalization) between treatment arms. An HR of 0.70 for the experimental arm means the risk of the event was 30% lower in treated patients compared to the control arm at any given time point — but it does not directly tell you how many additional months of life were gained. The K-M curve visualizes this over time, showing the proportion of participants remaining event-free as time passes.
The Number Needed to Treat (NNT) is the number of patients who must receive a treatment to produce one additional beneficial outcome compared to control. It is calculated as 1 / (absolute risk reduction). An NNT of 10 means you must treat 10 people to benefit one. The Number Needed to Harm (NNH) is the analogous measure for adverse effects. Comparing NNT to NNH helps clinicians make practical treatment decisions by putting risks and benefits on a common scale. A medicine with NNT of 5 and NNH of 100 has a very favorable benefit-harm ratio; one with NNT of 50 and NNH of 10 does not.
When evaluating a published RCT, the CONSORT checklist (Consolidated Standards of Reporting Trials) provides a structured framework. It specifies 25 items that should be reported in any well-conducted parallel-group RCT, including the randomization method, allocation concealment, blinding procedures, participant flow, and reasons for missing data. A trial that meets CONSORT standards provides the transparency needed for critical appraisal.
Equity in Research
The scientific value of a clinical trial depends not only on its methodological rigor but also on whether its participants are representative of the population that will ultimately use the treatment. For decades, clinical research systematically excluded large segments of the population, producing evidence that could not be reliably generalized to women, racial and ethnic minorities, older adults, and children.
Following the thalidomide tragedy and the DES (diethylstilbestrol) disaster, the FDA in 1977 recommended excluding women of childbearing potential from Phase I and early Phase II trials — a policy intended to protect fetuses that instead produced a massive evidence gap. For fifteen years, virtually every medicine was tested predominantly in men and then presumed to work the same way in women, despite well-documented sex differences in pharmacokinetics, immune responses, and medicine metabolism. The NIH Revitalization Act of 1993 finally required the NIH to include women and minorities in federally funded clinical trials and to conduct analyses by subgroup. The FDA followed with its own guideline in 1993, reversing the blanket exclusion policy.
Despite representing over 40% of the U.S. population, Black and Hispanic individuals are consistently underrepresented in clinical trials — often comprising fewer than 5-10% of trial populations even in diseases where they bear disproportionate burden. The consequences are concrete: differences in medicine metabolism due to genetic polymorphisms in cytochrome P450 enzymes, differential rates of adverse events (as documented for angiotensin-converting enzyme inhibitors and cough risk), and uncertainty about whether efficacy data from predominantly white populations generalizes to other groups.
The FDA's 2022 Diversity Action Plan guidance requires sponsors of Phase III trials to submit enrollment diversity plans specifying their goals for enrolling participants from historically underrepresented groups and the strategies they will use to achieve them. Community-based research sites, patient navigator programs, culturally and linguistically appropriate materials, and decentralized trial designs (allowing some study activities to be conducted remotely or at local facilities) are increasingly being used to reduce barriers to participation.
Children metabolize medicines differently than adults and face unique disease presentations that require dedicated study. The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) together create a framework requiring sponsors to conduct pediatric studies for medicines likely to be used in children, either as a condition of approval or in exchange for pediatric exclusivity (an additional 6 months of market exclusivity). The NIH Sex as a Biological Variable (SABV) policy, effective since 2016, requires NIH-funded researchers to account for sex as a biological variable in vertebrate animal and human studies, ensuring that sex-specific differences in biology are systematically investigated rather than assumed to be absent.
Compensation practices vary widely between trials. Many studies provide reimbursement for travel costs, parking, and time — particularly Phase I trials involving multiple clinic visits. Some trials offer modest additional payments. However, federal regulations require that compensation not be so large as to constitute an "undue inducement" that might cloud participants' judgment about risks. IRBs review all compensation plans to ensure they are not coercive. Study-related medical care and the experimental medicine are typically provided free of charge. Always ask specifically about what costs are covered and what compensation is offered before you enroll.
Not necessarily. If the trial uses a randomized controlled design with a placebo or active comparator arm, you may be assigned to the control group and not receive the experimental treatment. The probability of receiving the experimental medicine depends on the randomization ratio (e.g., 1:1 gives you a 50% chance; 2:1 gives you a 67% chance). Some trials are open-label single-arm studies where all participants receive the experimental medicine. Always ask the study team about the trial design and your probability of receiving the experimental treatment before you consent.
Absolutely. Voluntary participation is one of the most fundamental rights in clinical research. You can withdraw at any time, for any reason, without providing an explanation, and without any penalty or loss of benefits to which you are otherwise entitled — including access to your regular medical care. The research team may ask you to discuss your reasons, which helps the team improve its processes and understand the data, but you are under no obligation to share your reasons. If you withdraw, you will receive information about how your existing data will be handled in accordance with the protocol.
If you experience injury as a result of participating in a clinical trial, you are entitled to receive medical treatment for that injury. However, whether you will receive free medical treatment or compensation for injury depends on the specific trial and sponsor — there is no universal U.S. requirement that sponsors compensate participants for research-related injuries, though this is an active area of ethical debate. Industry-sponsored trials often have provisions for treatment of study-related injuries at no cost. The informed consent document must disclose whether compensation and treatment are available for research-related injuries. Before enrolling, ask specifically what the sponsor will provide if you experience a trial-related injury.
Legitimate trials are registered on ClinicalTrials.gov with an NCT number and have been reviewed and approved by an IRB or independent ethics committee. They operate under an IND with the FDA. Researchers cannot legally begin a study on humans without these approvals. Warning signs of potentially illegitimate "trials" include requests for you to pay to participate, no IRB approval number, no NCT registration, promises of guaranteed cure, or refusal to provide written informed consent documentation. You can verify a trial's registration status and IRB review by searching ClinicalTrials.gov and asking the research team directly for their IRB approval number.
Possibly, but it depends on the specific trial's eligibility criteria. Many trials have exclusion criteria related to concomitant medications — particularly medicines that are metabolized by the same enzymes as the experimental compound (creating medicine-medicine interaction risks) or immunosuppressants and anticoagulants. Some trials actively exclude anyone on other treatments to ensure clean pharmacokinetic data; others permit standard of care medications that are expected to be used alongside the experimental medicine. Bring a complete list of all medications — including over-the-counter medicines, vitamins, and supplements — to your initial conversation with the study coordinator.
The duration varies enormously based on trial phase, the condition being studied, and the endpoints being measured. Phase I trials typically last 1-2 years from first participant enrolled to last participant out. Phase II trials generally run 2-3 years. Phase III trials for serious conditions often span 3-7 years, and some cardiovascular and cancer trials run even longer to accumulate sufficient outcome events. Your individual participation period within a trial is usually shorter than the overall trial duration — it depends on the length of treatment and follow-up required by the protocol, which can range from weeks to several years.
A Data Safety Monitoring Board (DSMB) — also called a Data and Safety Monitoring Committee (DSMC) — is an independent group of experts (typically biostatisticians, clinicians, and ethicists) who are not otherwise involved in the trial and who periodically review unblinded interim safety and efficacy data as the trial progresses. The DSMB has the authority to recommend stopping the trial early — for safety concerns (unexpected serious harm to participants), for overwhelming efficacy (the new treatment is so clearly superior that continuing a control arm would be unethical), or for futility (the treatment is very unlikely to show benefit at trial completion). The existence of an independent DSMB provides an important safety layer above and beyond the IRB.
ClinicalTrials.gov allows filtering by age group — you can search specifically for pediatric trials (infants, children, adolescents) for your child's condition. The Children's Oncology Group (COG) coordinates pediatric cancer trials across more than 200 North American institutions and has its own searchable database. Disease-specific pediatric foundations — such as the Alex's Lemonade Stand Foundation (pediatric cancer) or the Pediatric Epilepsy Research Foundation — often maintain curated lists of open trials. Your child's specialist at a children's hospital is frequently the best initial resource, as they may know about trials at their own institution or through cooperative group networks.
Post-trial access to experimental treatments varies. Some sponsors offer expanded access or compassionate use programs for participants who benefited during the trial while regulatory review is ongoing. If the medicine receives regulatory approval, it becomes commercially available. If the medicine fails (does not receive approval), ongoing access is typically not provided — which underscores why the informed consent process must clearly communicate that trial participation does not guarantee long-term treatment. Some trials include open-label extension (OLE) phases that allow successful completers to continue receiving treatment while long-term safety data accumulates. Ask the study team before enrolling what will happen to your care at trial end.
External Resources